Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | OGN |
---|---|---|
09:32 ET | 50317 | 15.64 |
09:33 ET | 27834 | 15.745 |
09:35 ET | 6394 | 15.7 |
09:37 ET | 6407 | 15.6912 |
09:39 ET | 14531 | 15.65 |
09:42 ET | 36589 | 15.7 |
09:44 ET | 4690 | 15.725 |
09:46 ET | 9228 | 15.75 |
09:48 ET | 25347 | 15.75 |
09:50 ET | 6279 | 15.76 |
09:51 ET | 8594 | 15.81 |
09:53 ET | 17998 | 15.79 |
09:55 ET | 10243 | 15.73 |
09:57 ET | 3650 | 15.7701 |
10:00 ET | 9171 | 15.805 |
10:02 ET | 7847 | 15.77 |
10:04 ET | 8524 | 15.74 |
10:06 ET | 7077 | 15.755 |
10:08 ET | 14647 | 15.75 |
10:09 ET | 3208 | 15.7882 |
10:11 ET | 6277 | 15.81 |
10:13 ET | 8002 | 15.755 |
10:15 ET | 8959 | 15.815 |
10:18 ET | 18753 | 15.9 |
10:20 ET | 21875 | 15.92 |
10:22 ET | 11638 | 15.975 |
10:24 ET | 32311 | 15.945 |
10:26 ET | 15014 | 15.985 |
10:27 ET | 40195 | 16.0528 |
10:29 ET | 16031 | 16.045 |
10:31 ET | 6521 | 16.025 |
10:33 ET | 20055 | 16.06 |
10:36 ET | 10330 | 16.02 |
10:38 ET | 4220 | 16.005 |
10:40 ET | 3097 | 16.01 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Organon & Co | 3.9B | 3.2x | -14.04% |
Perrigo Company PLC | 3.8B | -26.9x | --- |
Bausch Health Companies Inc | 2.9B | -16.5x | --- |
Jazz Pharmaceuticals PLC | 7.7B | 17.8x | -3.53% |
Catalent Inc | 11.1B | -26.9x | --- |
Amneal Pharmaceuticals Inc | 2.6B | -12.3x | --- |
Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions. Its portfolio also includes VTAMA (tapinarof) cream, 1%, a nonbiologic, non-steroidal topical therapy, for treatment of mild, moderate, and severe plaque psoriasis in adults.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.9B |
---|---|
Revenue (TTM) | $6.4B |
Shares Outstanding | 257.5M |
Dividend Yield | 7.00% |
Annual Dividend Rate | 1.1200 USD |
Ex-Dividend Date | 11-12-24 |
Pay Date | 12-12-24 |
Beta | 0.72 |
EPS | $5.04 |
Book Value | $-0.27 |
P/E Ratio | 3.2x |
Price/Sales (TTM) | 0.6 |
Price/Cash Flow (TTM) | 2.5x |
Operating Margin | 12.20% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.